X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ALEMBIC PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ALEMBIC PHARMA CIPLA/
ALEMBIC PHARMA
 
P/E (TTM) x 45.7 29.6 154.2% View Chart
P/BV x 3.9 6.8 57.9% View Chart
Dividend Yield % 0.3 0.7 47.0%  

Financials

 CIPLA   ALEMBIC PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
ALEMBIC PHARMA
Mar-16
CIPLA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs622792 78.6%   
Low Rs458443 103.5%   
Sales per share (Unadj.) Rs181.9167.0 108.9%  
Earnings per share (Unadj.) Rs12.938.2 33.7%  
Cash flow per share (Unadj.) Rs29.342.0 69.8%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.40.6 57.2%  
Book value per share (Unadj.) Rs155.784.9 183.4%  
Shares outstanding (eoy) m804.51188.52 426.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.7 80.4%   
Avg P/E ratio x42.016.2 259.4%  
P/CF ratio (eoy) x18.414.7 125.3%  
Price / Book Value ratio x3.57.3 47.7%  
Dividend payout %15.510.5 148.3%   
Avg Mkt Cap Rs m434,516116,383 373.4%   
No. of employees `00023.0NA-   
Total wages/salary Rs m26,3384,214 625.0%   
Avg. sales/employee Rs Th6,349.1NM-  
Avg. wages/employee Rs Th1,143.0NM-  
Avg. net profit/employee Rs Th449.3NM-  
INCOME DATA
Net Sales Rs m146,30231,487 464.6%  
Other income Rs m2,28755 4,150.5%   
Total revenues Rs m148,58931,542 471.1%   
Gross profit Rs m24,75810,060 246.1%  
Depreciation Rs m13,229722 1,832.1%   
Interest Rs m1,59437 4,331.0%   
Profit before tax Rs m12,2229,356 130.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-70-2 4,660.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7982,160 83.2%   
Profit after tax Rs m10,3547,194 143.9%  
Gross profit margin %16.931.9 53.0%  
Effective tax rate %14.723.1 63.7%   
Net profit margin %7.122.8 31.0%  
BALANCE SHEET DATA
Current assets Rs m87,37015,066 579.9%   
Current liabilities Rs m33,0817,674 431.1%   
Net working cap to sales %37.123.5 158.1%  
Current ratio x2.62.0 134.5%  
Inventory Days Days8767 129.9%  
Debtors Days Days6241 153.4%  
Net fixed assets Rs m111,5678,237 1,354.4%   
Share capital Rs m1,609377 426.8%   
"Free" reserves Rs m123,64515,416 802.0%   
Net worth Rs m125,25416,005 782.6%   
Long term debt Rs m36,4540-   
Total assets Rs m209,53224,594 852.0%  
Interest coverage x8.7255.2 3.4%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.71.3 54.5%   
Return on assets %5.729.4 19.4%  
Return on equity %8.344.9 18.4%  
Return on capital %8.558.7 14.5%  
Exports to sales %34.255.7 61.4%   
Imports to sales %8.310.4 80.0%   
Exports (fob) Rs m50,05017,551 285.2%   
Imports (cif) Rs m12,2033,283 371.7%   
Fx inflow Rs m51,06617,811 286.7%   
Fx outflow Rs m17,6785,318 332.4%   
Net fx Rs m33,38812,493 267.3%   
CASH FLOW
From Operations Rs m23,8249,304 256.1%  
From Investments Rs m-13,127-3,105 422.8%  
From Financial Activity Rs m-13,239-1,959 675.7%  
Net Cashflow Rs m-2,4784,240 -58.4%  

Share Holding

Indian Promoters % 16.0 74.1 21.6%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 2.9 420.7%  
FIIs % 23.7 9.1 260.4%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 13.9 188.5%  
Shareholders   161,166 49,328 326.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 16, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS